Although histological outcomes remain the gold standard in MASH drug trials, non-invasive markers such as serum ALT levels are increasingly relevant in clinical practice due to the limitations of liver biopsy, including invasiveness, complication risk, and sampling variability [17]. This evidence concerns the gene GPT and metabolic dysfunction-associated steatohepatitis.